Edition:
United States

Tetraphase Pharmaceuticals Inc (TTPH.OQ)

TTPH.OQ on NASDAQ Stock Exchange Global Select Market

2.18USD
1:44pm EST
Change (% chg)

$0.06 (+2.83%)
Prev Close
$2.12
Open
$2.10
Day's High
$2.21
Day's Low
$2.09
Volume
243,681
Avg. Vol
206,449
52-wk High
$9.69
52-wk Low
$2.06

Select another date:

Tue, Feb 20 2018

BRIEF-Tetraphase Pharma Enters Exclusive Development And Commercialization Agreement With Everest Medicines

* TETRAPHASE PHARMACEUTICALS ENTERS INTO EXCLUSIVE DEVELOPMENT AND COMMERCIALIZATION AGREEMENT WITH EVEREST MEDICINES FOR ERAVACYCLINE IN CHINA

Tetraphase's antibiotic fails late-stage study, shares plummet

Tetraphase Pharmaceuticals Inc said on Tuesday its lead experimental antibiotic to treat serious infections did not meet the main goals in a late-stage study, sending its shares plunging more than 60 percent in after-market trading.

Tetraphase's antibiotic fails late-stage study, shares plummet

Feb 13 Tetraphase Pharmaceuticals Inc said on Tuesday its lead experimental antibiotic to treat serious infections did not meet the main goals in a late-stage study, sending its shares plunging more than 60 percent in after-market trading.

BRIEF-Tetraphase Posts Top-Line Results From IGNITE3 Phase 3 Clinical Trial Of Eravacycline In CUTI

* TETRAPHASE ANNOUNCES TOP-LINE RESULTS FROM IGNITE3 PHASE 3 CLINICAL TRIAL OF ERAVACYCLINE IN COMPLICATED URINARY TRACT INFECTIONS (CUTI)

BRIEF-Tetraphase Pharmaceuticals Files For Mixed Shelf Of Up To $150 Mln

* FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING Source text: (http://bit.ly/2n8xDCf) Further company coverage:

BRIEF-Tetraphase Pharmaceuticals Announces Submission Of NDA To FDA For Eravacycline To Treat Intra-Abdominal Infections

* TETRAPHASE PHARMACEUTICALS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION TO FDA FOR ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI)

BRIEF-Millennium Management Llc Reports 5.3 Pct Passive Stake In Tetraphase Pharmaceuticals As On Dec 14

* MILLENNIUM MANAGEMENT LLC REPORTS 5.3 PERCENT PASSIVE STAKE IN TETRAPHASE PHARMACEUTICALS AS ON DEC 14 - SEC FILING Source text: (http://bit.ly/2kt52WQ) Further company coverage:

BRIEF-Tetraphase Pharmaceuticals Q3 loss per share $0.63

* Tetraphase pharmaceuticals reports third quarter 2017 financial results and highlights recent clinical and corporate achievements

BRIEF-Tetraphase Pharmaceuticals signs commercial supply agreement with Finorga

* Tetraphase Pharmaceuticals Inc says ‍on October 16 co and finorga sas entered into a commercial supply agreement​ - sec filing

BRIEF-TETRAPHASE PHARMACEUTICALS APPOINTS KAM UNNINAYAR AS CFO

* TETRAPHASE PHARMACEUTICALS APPOINTS KAM UNNINAYAR AS CHIEF FINANCIAL OFFICER

Select another date: